bioRxivCancer Biology
Patient-derived tumor spheroid cultures as a promising tool to assist personalized therapeutic decisions in breast cancer
Abstract
Breast cancer is the most common cause of cancer related death in women. Treatment of breast cancer has many limitations including a lack of accurate biomarkers to predict success of chemotherapy and intrinsic resistance of a significant group of patients to the gold standard of therapy. Therefore, new tools are needed to provide doctors with guidance in choosing the most effective treatment plan for a particular patient and thus to increase the survival rate for breast cancer patients. Here, we present a successful method to grow in vitro spheroids from primary breast cancer tissue. Samples were received in accordance with relevant ethical guidelines and regulations. After tissue dissociation, in vitro spheroids were generated in a scaffold-free 96-well plate format. Spheroid composition was investigated by immunohistochemistry (IHC) of epithelial (Pan Cytokeratin (panCK)), stromal (Vimentin) and breast cancer-specific markers (ER, PR, HER2, GATA-3). Growth and cell viability of the spheroids were assessed upon treatment with multiple anti-cancer compounds. Students t-test and two-way ANOVA test were used to determine statistical significance. We were able to successfully grow spheroids from 27 out of 31 samples from surgical resections of breast cancer tissue from previously untreated patients. Recapitulation of the histopathology of the tissue of origin was confirmed. Furthermore, a drug panel of standard first- and second-line chemotherapy drugs used to treat breast cancer was applied to assess the viability of the patient-derived spheroids and revealed variation between samples in the response of the spheroids to different drug treatments. We investigated the feasibility and the utility of an in vitro patient-derived spheroid model for breast cancer therapy, and we conclude that spheroids serve as a highly effective platform to explore cancer therapeutics and personalized treatment efficacy. These results have significant implications for the application of this model in clinical personalized medicine.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies
Tam Binh V. Bui, Denise M. Wolf, … Jennifer M. Rosenbluth·bioRxiv·Aug 24, 2025
- A simple and cost-effective method for generating spheroids from triple-negative breast cancer cell line (MDA-MB-231)
Ramón Cervantes-Rivera, Luisa Nirvana Gonzalez-Fernandez, … Joel Edmundo López-Meza·BIO-PROTOCOLPeer-reviewed·Jan 1, 2026
- A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology
K. P. Guillen, M. Fujita, … A. L. Welm·bioRxiv·Feb 28, 2021
- Tumor-on-Chip as a Personalised Platform for Rapid Drug-Testing in Breast Cancer
Clara Helal, Léa Pinon, … Stéphanie Descroix·bioRxiv·Oct 26, 2025
- Single cell-derived spheroids for real-time growth and metabolomic studies in breast cancer
Margarida Esteves, Fernanda Almeida da Silva de Sá Oliveira, … Sara Abalde‐Cela·bioRxiv·Feb 28, 2025
- Personalized models of breast cancer desmoplasia reveal biomechanical determinants of drug penetration
G. S. Offeddu, E. Cambria, … R. D. Kamm·bioRxiv·Dec 12, 2021